Last reviewed 2026-04-20 · How we verify

Factive (GEMIFLOXACIN MESYLATE)

Factive (Gemifloxacin mesylate) is a quinolone antimicrobial small molecule developed by LG Life Sciences and currently owned by LG Chem Ltd. It was FDA-approved in 2003 for the treatment of various bacterial infections, including pneumonia and bronchitis. Factive is off-patent and has a generic manufacturer. The drug has a half-life of 8.3 hours. It is used to treat a range of bacterial infections, including those caused by Haemophilus influenzae and Klebsiella pneumoniae.

At a glance

Approved indications

• Acute bacterial bronchitis
• Acute exacerbation of chronic bronchitis
• Bacterial pneumonia
• Chlamydial pneumonia
• Haemophilus influenzae pneumonia
• Moraxella Catarrhalis Pneumonia
• Pneumococcal pneumonia
• Pneumonia due to Klebsiella pneumoniae
• Pneumonia due to Mycoplasma pneumoniae

Common side effects

• Headache
• Nausea
• Rash
• Diarrhea
• Abdominal pain
• Dizziness
• Vomiting
• Increased ALT
• Increased platelets
• Increased AST
• Urticaria
• Increased creatine phosphokinase

Serious adverse events

• Rash (discontinuation)
• Nausea (discontinuation)
• Diarrhea (discontinuation)
• Urticaria (discontinuation)
• Vomiting (discontinuation)
• Photosensitivity/phototoxicity reactions
• Thrombocytopenia
• Granulocytopenia
• Anemia
• Eosinophilia

Drug interactions

• High Risk QT Prolonging Agents
• dronedarone
• hydrocortisone
• methylprednisolone
• prednisolone
• prednisone

Key clinical trials

• A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
• EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY (PHASE1)
• Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis (PHASE3)
• Fluoroquinolone Associated Disability
• Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma (EARLY_PHASE1)
• Efficacy of Combination Therapies for Gonorrhea Treatment (PHASE4)
• Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection (PHASE3)
• An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.